Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
33 hedge funds and large institutions have $172M invested in Mirati Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
27% more funds holding
Funds holding: 26 → 33 (+7)
22% more capital invested
Capital invested by funds: $141M → $172M (+$31.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$4.99M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.95M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.56M |
| 5 |
Morgan Stanley
New York
|
+$952K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.4M |
| 2 |
First Eagle Investment Management
New York
|
-$4.93M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.23M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$832K |
| 5 |
BC
Broadfin Capital
New York
|
-$614K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $68K | +$59.9K | +2,882 | +426% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $52K | +$16.4K | +787 | +42% |
|
|
BIT
28
BlackRock Institutional Trust
San Francisco,
California
| $42K | +$46.2K | +2,224 | New |
|
29
Barclays
London,
United Kingdom
| $17K | +$18.4K | +887 | New |
|
|
TC
30
TradeLink Capital
Chicago,
Illinois
| $10K | +$10.4K | +500 | New |
|
|
BRWM
31
B. Riley Wealth Management
Memphis,
Tennessee
| $2K | +$1.7K | +82 | New |
|
32
Citigroup
New York
| $1K | +$603 | +29 | New |
|
|
33
Alyeska Investment Group
Chicago,
Illinois
| – | -$832K | -50,000 | Closed |
|
|
TC
34
TFS Capital
West Chester,
Pennsylvania
| – | -$291K | -17,510 | Closed |
|
|
SM
35
Sabby Management
Miami Beach,
Florida
| – | -$203K | -12,213 | Closed |
|
|
AP
36
Advisors Preferred
Rockville,
Maryland
| – | -$6K | -385 | Closed |
|
37
BlackRock
New York
| – | +$395 | +19 | New |
|
MRTX Hedge Fund Activity: Q1 2014 in Review
33 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2014, worth a combined $172M — up 22% from $141M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MRTX positions and 4 closed out — a net gain of 7 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $14.6M. The largest seller was Tang Capital Management, cutting an estimated $10.4M.
- 33 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2014, up from 26 in Q4 2013.
- Funds reported $172M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2014, up 22% quarter-over-quarter.
- 11 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2014 and 4 closed out, a net change of +7 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $14.6M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2014 was Tang Capital Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2014.